In the setting of viral infection, miR-122 appears to have opposite actions, as it promotes Hepatitis C Virus (HCV) replication by binding the region at the 5′-UTR of the HCV RNA genome, whereas it inhibits HBV replication through cyclin-G1-modulated p53 activity [54] and NDRG3 (a member of the N-myc downstream-regulated gene) [55] or directly by binding to HBV pregenomic RNA [56]. The gene discussed is TP53; the disease is viral infectious disease.